摘要
目的：探讨齐拉西酮、利培酮和氯丙嗪治疗对首发精神分裂症患者认知功能的影响。方法将96例首发精神分裂症患者随机分成3组，每组32例，分别口服齐拉西酮、利培酮和氯丙嗪治疗，观察8周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应，威斯康星卡片分类测验、数字划消测验和修订韦氏成人记忆量表评定认知功能。结果治疗8周末齐拉西酮组总有效率为86．67％，利培酮组为83．33％，氯丙嗪组为85．71％，3组总有效率比较差异无显著性（P＞0．05）；齐拉西酮组、利培酮组认知功能各项测验指标均较治疗前有显著改善（P＜0．01），氯丙嗪组则无显著变化（P＞0．05）；齐拉西酮组和利培酮组不良反应发生率显著低于氯丙嗪组（P＜0．05）。结论齐拉西酮、利培酮和氯丙嗪治疗首发精神分裂症疗效显著且相当，但齐拉西酮和利培酮能改善患者的认知功能，安全性更高，显著优于氯丙嗪治疗。
Objective To explore the influence of ziprasidone ,risperidone and chloropromazine on cogni-tive function of first-episode schizophrenics .Methods Ninety-six patients with first-episode schizophrenia were assigned to three groups （n=32） receiving ziprasidone ,risperidone or chlorpromazine for 8 weeks . Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS ） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） at baseline and at the end of the 8th week ,and cog-nitive functions with the Wisconsin Card Sorting Test （WCST ） ,Cancellation Test （CT ） and Wechsler Memory Scale revised in China （WMS-RC） .Results At the end of the 8th week total effective rate was re-spectively 86 .67% in ziprasidone ,83 .33% in risperidone and 85 .71% in chlorpromazine group ,which showed no significant differences （P〉0 .05）;each testing index of cognitive function improved more nota-bly in both ziprasidone and risperidone group compared with pretreatment （P〈0 .01） ,there were no nota-ble changes in those indexes in chlorpromazine group （P〉0 .05）;the incidences of adverse reactions were significantly lower in ziprasidone and risperidone than chlorpromazine group （P〈0 .05） .Conclusion Ziprasidone ,risperidone and chloropromazine have an evident and equivalent effect in the treatment of first-episode schizophrenia ,but ziprasidone and risperidone could improve patients’ cognitive function and has higher safety compared with chlorpromazine treatment .
出处
《临床心身疾病杂志》
CAS
2013年第6期556-559,共4页
Journal of Clinical Psychosomatic Diseases
